CCXI:NSD-ChemoCentryx, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 14.37

Change

0.00 (0.00)%

Market Cap

USD 1.00B

Volume

1.65M

Avg Analyst Target

USD 22.60 (+57.27%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD140.07B 233.80 177.21
BNTX BioNTech SE

N/A

USD68.10B 51.40 36.74
REGN Regeneron Pharmaceuticals, Inc

N/A

USD62.47B 16.69 13.10
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD51.90B 19.11 12.98
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene, Ltd

N/A

USD29.28B N/A N/A
GMAB Genmab A/S

N/A

USD29.00B 33.07 3.64
SGEN Seagen Inc

N/A

USD26.42B 40.63 36.27
RPRX Royalty Pharma plc

N/A

USD24.49B 33.25 14.58
ALNY Alnylam Pharmaceuticals, Inc

N/A

USD21.44B N/A N/A

ETFs Containing CCXI

Symbol Name Weight Mer Price(Change) Market Cap
SBIO ALPS ETF Trust - ALPS Med.. 0.00 % 0.50 %

N/A

USD0.23B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -76.79% 1% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -76.79% 1% F 1% F
Trailing 12 Months  
Capital Gain -72.47% 4% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.47% 4% F 2% F
Trailing 5 Years  
Capital Gain 215.82% 83% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 215.82% 83% B 82% B-
Average Annual (5 Year Horizon)  
Capital Gain 123.10% 92% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 123.10% 91% A- 95% A
Risk Return Profile  
Volatility (Standard Deviation) 204.91% 11% F 6% F
Risk Adjusted Return 60.07% 85% B 77% C+
Market Capitalization 1.00B 73% C 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 39.70 22% F 27% F
Price/Book Ratio 2.78 61% D- 50% F
Price / Cash Flow Ratio -12.35 66% D 75% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -30.10% 75% C 37% F
Return on Invested Capital -20.65% 76% C 27% F
Return on Assets -11.20% 81% B- 26% F
Debt to Equity Ratio 14.72% 48% F 66% D
Technical Ratios  
Short Ratio 1.54 72% C- 64% D
Short Percent 10.79% 26% F 17% F
Beta 1.44 45% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.